Key Insights From the DEBBRAH and HER2CLIMB-02 Studies

Panelists discuss a brief overview of recent data on combination systemic therapies for the treatment of advanced HER2+ breast cancer, including studies such as DESTINY-Breast03, DEBBRAH, HER2CLIMB-02, and EMILIA, and they analyze which patient populations may benefit most from each therapy option based on the available data.

EP: 1.Overview of HER2 Breast Cancer

EP: 2.HER2+ Breast Cancer Diagnosis: Insights From Patients and Clinicians

EP: 3.Coordinating Care for HER+ Breast Cancer Patients: A Multidisciplinary Approach

EP: 4.Multidisciplinary Care of HER2+ Breast Cancer: A Patient Perspective

EP: 5.Tailoring Patient Education and Resources in HER2+ Breast Cancer

EP: 6.Navigating HER2+ Breast Cancer Treatment: A Patient's Journey

EP: 7.Navigating Systemic Therapy Options in HER2+ Breast Cancer

EP: 8.Key Insights from the HER2CLIMB Trial

Now Viewing

EP: 9.Key Insights From the DEBBRAH and HER2CLIMB-02 Studies

EP: 10.BRIDGET Trial: Strategies in Maintenance Therapy for HER2+ Breast Cancer with Brain Metastases

EP: 11.Preparing Patients for Treatment: Education, Administration and Adverse Effect Management in HER2+ Breast Cancer

EP: 12.Patient Perspectives on Managing Adverse Effects from Capecitabine, Trastuzumab, and Tucatinib

1. Dr Iyengar: Please provide a brief overview of other recent data in combination systemic therapies for the treatment of advanced RCC. 
   1. DESTINY-Breast03
   2. DEBBRAH
   3. HER2CLIMB-02
   4. EMILIA
2. Given the available data, for which patient population do you prefer each therapy option and why?

Recent Videos